Evenity (Romosozumab) Pediatric (Under 12) Monitoring

Why Romosozumab Is Not Approved for Children Under 12

Romosozumab received FDA approval in April 2019 specifically for postmenopausal women with osteoporosis at high fracture risk. The prescribing information contains no pediatric indication, and no completed randomized controlled trial has evaluated the drug in children under 12 years of age. The FDA's prescribing information for Evenity states that safety and efficacy in pediatric patients have not been established.

The Sclerostin Biology in Growing Bone

Romosozumab works by binding and inhibiting sclerostin, a protein encoded by the SOST gene that normally suppresses Wnt signaling in osteoblasts. Blocking sclerostin increases bone formation markers (P1NP) while transiently lowering bone resorption markers (CTX). This dual action produces rapid gains in bone mineral density.

In adults, that mechanism is well-characterized. In children under 12, the same Wnt pathway governs longitudinal bone growth, endochondral ossification at growth plates, and skeletal modeling. Interfering with sclerostin signaling during active growth carries theoretical risks of altered growth plate biology that have not been studied in long-term pediatric trials. Research published in Bone confirms that sclerostin expression is active in pediatric growth plates, meaning the drug's downstream effects on a developing skeleton remain genuinely unknown.

Regulatory and Ethical Framework

Because no pediatric data exist, any clinician considering romosozumab for a child under 12 is operating under 21 CFR 312 for investigational use or under standard off-label prescribing authority. The American Academy of Pediatrics position on off-label drug use, outlined by Shaddy and Denne (Pediatrics, 2010), requires that off-label prescribing be supported by sound scientific evidence, documented in the medical record, and accompanied by informed consent specifying the investigational nature.

Institutional review board involvement and pediatric endocrinology consultation are not optional in this context. They are the standard of care.

Indications That Might Prompt Off-Label Consideration

Severe childhood osteoporosis is rare. When it does occur, it is almost always secondary to an underlying condition rather than primary.

Conditions Associated With Severe Pediatric Osteoporosis

Conditions that can produce fracture burden severe enough for a clinician to consider a bone anabolic agent in a young child include:

• Osteogenesis imperfecta (OI) types III and IV, where bisphosphonate therapy may be insufficient
• Glucocorticoid-induced osteoporosis from long-term steroid use in conditions such as juvenile idiopathic arthritis or Duchenne muscular dystrophy
• Immobilization osteoporosis in children with cerebral palsy or spinal muscular atrophy
• Rare monogenic conditions such as SOST-related sclerosteosis, where the pathway is already constitutively dysregulated

The 2017 ISCD Pediatric Official Positions define clinically significant osteoporosis in children as a spine or whole-body-less-head Z-score at or below -2.0 combined with a history of clinically significant fracture. Meeting that definition with bisphosphonate failure is the threshold most pediatric specialists would require before even discussing romosozumab.

When Bisphosphonates Are Insufficient

Bisphosphonates, particularly intravenous pamidronate (3 mg/kg/year in divided doses) and zoledronic acid, remain first-line anabolic-adjacent therapy for severe pediatric osteoporosis. A 2021 review in JBMR found that zoledronic acid at 0.05 mg/kg IV annually improved lumbar spine Z-scores by a mean of 0.6 to 1.2 SD over two years in children with OI.

Romosozumab would only enter the picture after documented bisphosphonate failure or intolerance, not as initial therapy.

Pre-Treatment Monitoring and Workup

Before any dose of romosozumab in a child under 12, a structured pre-treatment evaluation is required. The FDA label mandates several checks even in adults; pediatric use demands additional layers.

Baseline Laboratory Panel

The following labs should be obtained no more than 4 weeks before the first injection:

• Serum calcium (corrected for albumin) and ionized calcium
• Serum phosphate and magnesium
• 25-hydroxyvitamin D (target above 30 ng/mL before initiating)
• Parathyroid hormone (PTH) to rule out secondary hyperparathyroidism
• Serum creatinine and estimated GFR (eGFR) using a pediatric-validated equation such as the Schwartz formula
• Bone turnover markers: P1NP and CTX-I as baseline references
• Complete blood count, liver function panel

Hypocalcemia is a known complication of romosozumab. The FDA label explicitly states that pre-existing hypocalcemia must be corrected before initiating treatment. In children, this carries added weight because ionized calcium also affects neuromuscular function and cardiac rhythm.

Baseline Imaging

DXA of the lumbar spine (L1-L4) and total body less head is the standard for pediatric bone density measurement per ISCD 2019 guidelines. Results must be reported as age- and sex-matched Z-scores, not T-scores. T-scores are meaningless in pediatric patients who have not yet reached peak bone mass.

Vertebral fracture assessment or lateral spine X-ray is recommended to identify pre-existing compression fractures, which change fracture risk classification. Wrist X-ray for bone age should be obtained to confirm skeletal maturity status.

Cardiovascular Baseline Assessment

The FDA Black Box Warning on Evenity reads: "EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death. EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." In the ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, the romosozumab group showed serious cardiovascular adverse events in 2.5% of patients compared with 1.9% in the alendronate group over 12 months.

For a child under 12, that cardiovascular signal demands a pediatric cardiology consult, resting ECG, and blood pressure measurement at baseline. Children with congenital heart disease, arrhythmia history, or hypertension are not candidates.

Monitoring During the 12-Month Treatment Course

The adult regimen of 210 mg subcutaneous injection once monthly for 12 doses has no validated pediatric equivalent. No weight-based dosing algorithm exists in published literature. Any dose selected for a child is entirely extrapolated from adult pharmacokinetics.

Monthly Safety Checks (Months 1 Through 12)

At each monthly visit when the injection is given, the following should be documented:

• Blood pressure and resting heart rate
• Symptom screening for jaw pain (osteonecrosis risk), thigh or groin pain (atypical femoral fracture risk), and neurological symptoms suggesting stroke
• Injection site assessment for erythema, swelling, or hypersensitivity

Serum calcium should be rechecked within 2 weeks of the first dose, because the rapid increase in bone formation triggered by romosozumab consumes calcium and can precipitate hypocalcemia even in patients who were normocalcemic at baseline. After the first dose, serum calcium monitoring frequency can be extended to every 3 months if values remain stable.

Quarterly Growth and Development Surveillance

Children under 12 require monitoring parameters that adult protocols do not include. Every 3 months throughout the treatment course, the clinical team should document:

• Standing height (or supine length if under 24 months) and weight, plotted on CDC or WHO growth charts
• Height velocity (cm/year), calculated from sequential measurements
• Tanner staging to capture pubertal progression, because puberty accelerates bone accrual and alters the drug's risk-benefit equation
• Assessment for back pain, which can indicate vertebral compression even in the absence of trauma

A decrease in height velocity below the age-expected percentile warrants immediate orthopedic and endocrinology review. Animal studies cited in the FDA Evenity pharmacology review showed effects on bone growth in juvenile rats at doses producing systemic exposure comparable to the human therapeutic range. That preclinical signal is the reason growth plate monitoring is not optional.

Bone Turnover Markers at Months 1, 6, and 12

P1NP and CTX-I should be measured at months 1, 6, and 12. In adults, romosozumab produces a rapid rise in P1NP (peaking around month 1) followed by a plateau, while CTX-I shows an initial decline. If a treated child shows no rise in P1NP by month 1, adherence and injection technique should be verified before continuing the course.

These markers also serve as an early signal that the 12-month anabolic window is closing. The P1NP response typically attenuates after month 9 even with continued dosing, consistent with data from the FRAME trial (N=7,180) published in the New England Journal of Medicine in 2016, where romosozumab increased lumbar spine BMD by 13.3% over 12 months.

Cardiovascular Monitoring Protocol

Cardiovascular monitoring deserves its own section given the Black Box Warning. The ARCH trial's cardiovascular imbalance remains incompletely explained mechanistically. One hypothesis involves rapid calcium shifts altering vascular calcification dynamics; another involves the drug's effect on Wnt signaling in vascular smooth muscle cells.

Frequency and Tests

• Resting ECG at baseline, month 3, month 6, and end of course (month 12)
• Blood pressure at every monthly visit
• Fasting lipid panel at baseline and month 6 (Wnt signaling affects lipid metabolism in some contexts)
• Immediate discontinuation if the patient develops signs of myocardial ischemia, stroke, or new arrhythmia

The American Heart Association's pediatric cardiovascular risk statement provides the reference range for blood pressure by age and height percentile. Use it at every visit.

Children With Pre-Existing Cardiac Conditions

Any child with a history of congenital heart disease, cardiomyopathy, prolonged QTc, or a prior ischemic event should not receive romosozumab. Full stop. The adult Black Box Warning excludes patients with MI or stroke within 12 months; in children, that exclusion should be extended to any active or recent serious cardiac diagnosis.

Post-Treatment Monitoring and Sequential Therapy

The anabolic benefit of romosozumab is partially lost without antiresorptive consolidation immediately following the 12-dose course. In the ARCH trial, patients who transitioned from romosozumab to alendronate showed a 48% reduction in new vertebral fractures compared with those who received alendronate from the start, as reported in the NEJM 2017 publication.

Sequential Therapy in Children

Transitioning a child under 12 to an antiresorptive agent after romosozumab introduces a second layer of off-label decision-making. Bisphosphonates (zoledronic acid or pamidronate) are the most studied antiresorptives in pediatric populations. Denosumab has been used in children with OI and giant cell tumor, but rebound hypercalcemia and vertebral fractures after discontinuation are documented risks, as described in a 2021 JBMR Plus case series.

The sequential therapy plan must be decided before romosozumab is started, not after month 12, because timing of the first antiresorptive dose matters.

Post-Course DXA and Fracture Reassessment

DXA should be repeated within 3 to 6 months of completing the 12-dose course to quantify the BMD response. A follow-up lateral spine X-ray or VFA assesses whether any new vertebral changes occurred silently during treatment. If BMD Z-score improved by 0.5 SD or more and no new fractures occurred, the treatment course can be considered a partial success. That threshold is adapted from the ISCD pediatric monitoring guidance.

Dosing Considerations: What the Literature Does and Does Not Say

No phase II or III trial has established a weight-based romosozumab dose for children. The adult dose of 210 mg monthly delivers approximately 2.8 mg/kg in a 75 kg adult. Extrapolating that mg/kg figure to a 20 kg child would yield approximately 56 mg per injection, but that arithmetic has never been tested for safety or efficacy in pediatric subjects.

Pharmacokinetic Extrapolation Limitations

Pediatric pharmacokinetics differ from adult PK in renal clearance rates, volume of distribution relative to body composition, and hepatic enzyme maturity. The FDA's Pediatric Research Equity Act (PREA) requires sponsors to submit pediatric study plans for drugs that might benefit pediatric patients, but Amgen received a waiver for the under-12 population on the basis that osteoporosis does not occur in that age group in the same form as postmenopausal disease.

That waiver does not mean the drug is safe in children. It means no data were collected.

Practical Guidance for Off-Label Dosing Decisions

Any center treating a child under 12 with romosozumab should:

1. Submit the case to an IRB or institutional ethics board before initiation
2. Consult with a pediatric pharmacologist to model expected exposure based on body weight and eGFR
3. Start with a dose at or below the adult mg/kg equivalent and plan for therapeutic drug monitoring if assays are available
4. Register the patient in a case registry or observational database to contribute to the sparse evidence base

The European Society for Paediatric Endocrinology (ESPE) position paper on bone health recommends that novel bone agents in children be used only within structured research frameworks wherever possible.

Special Populations Within the Under-12 Age Group

Infants and Toddlers (Under 3 Years)

Romosozumab use in infants and toddlers has no published case reports or trials. Bone modeling in the first three years of life is governed heavily by Wnt signaling, and sclerostin expression rises progressively through early childhood. The theoretical risks in this subgroup are substantially higher than in school-age children, and no plausible clinical benefit has been described that would justify use.

Children With Renal Impairment

The FDA label notes that romosozumab has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) or in patients on dialysis. Children with chronic kidney disease stage 4 or 5 are at risk for renal osteodystrophy, which has its own management algorithm through KDIGO 2017 CKD-MBD guidelines. Using romosozumab in a child with eGFR <30 would be extremely high-risk and is not supported by any published data.

Children With Osteogenesis Imperfecta

OI is the pediatric bone disorder with the most accumulated experience using novel agents. A 2020 case report in Osteoporosis International described a 14-year-old with severe OI who received romosozumab off-label with a BMD Z-score improvement of 1.1 SD at the lumbar spine after 12 months. That patient's age places them above the under-12 threshold, but the case offers the closest published analog for clinical context in a pediatric population with severe disease.

No equivalent published case exists for a child under 12. Any treating physician would be generating entirely novel clinical data.